Janney Montgomery Scott LLC Buys Shares of 15,210 Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Janney Montgomery Scott LLC purchased a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm purchased 15,210 shares of the specialty pharmaceutical company's stock, valued at approximately $1,888,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth about $25,000. Quadrant Capital Group LLC raised its holdings in Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after purchasing an additional 101 shares during the period. Elequin Capital LP increased its stake in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after buying an additional 183 shares in the last quarter. CoreFirst Bank & Trust purchased a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $28,000. Finally, Allianz SE purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $29,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Trading Up 0.4%

Shares of Jazz Pharmaceuticals stock opened at $107.51 on Friday. The company has a debt-to-equity ratio of 1.28, a current ratio of 3.38 and a quick ratio of 2.97. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The company has a market capitalization of $6.51 billion, a P/E ratio of 14.33, a P/E/G ratio of 4.62 and a beta of 0.33. The business has a 50 day moving average price of $108.55 and a 200 day moving average price of $119.66.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The business had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. During the same quarter last year, the firm posted $2.68 earnings per share. The company's revenue was down .5% on a year-over-year basis. Sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 500 shares of the company's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $107.90, for a total transaction of $53,950.00. Following the completion of the sale, the chief executive officer now directly owns 438,473 shares of the company's stock, valued at approximately $47,311,236.70. This represents a 0.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Seamus Mulligan purchased 1,621 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were acquired at an average cost of $103.00 per share, with a total value of $166,963.00. Following the completion of the transaction, the director now owns 101,621 shares in the company, valued at $10,466,963. This trade represents a 1.62% increase in their position. The disclosure for this purchase can be found here. Insiders sold 3,000 shares of company stock valued at $355,925 in the last ninety days. Company insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on JAZZ shares. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Wall Street Zen lowered Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Needham & Company LLC reaffirmed a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Robert W. Baird lowered their price target on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Finally, Truist Financial lifted their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $184.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.